Browse Biological products industry topic

Product development subtopic

Articles 1-100 out of 100 article(s) Title Author Type Date Words StemCells, Inc. Initiates Landmark Trial Targeting "Communication Highway" of the Brain. Nov 23, 2009 1683 Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC. Nov 19, 2009 951 StemCells, Inc. Provides Update on NCL Program Meeting with FDA. Nov 18, 2009 1281 Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design. Nov 17, 2009 1037 United States : Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design. Nov 17, 2009 422 Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System. Nov 16, 2009 152 Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75. Nov 16, 2009 705 Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension. Nov 2, 2009 1457 Juvaris BioTherapeutics Initiates Phase 2 Study of Influenza Vaccine Adjuvant in Elderly Population. Nov 2, 2009 594 Enzo Biochem Reports on Favorable Clinical Trial of EGS21 for Treatment of Non-Alcoholic Steatohepatitis. Clinical report Nov 2, 2009 874 United States : Gilead Sciences to present Viread Phase III clinical trial data. Nov 2, 2009 432 Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread[R] For Chronic Hepatitis B. Oct 31, 2009 2675 Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial. Oct 19, 2009 803 Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine under Its "Fillanthropy[TM] Program". Oct 15, 2009 900 United States : Vaccine trial showing positive results for Vical. Oct 12, 2009 136 Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial. Oct 5, 2009 749 Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting. Sep 29, 2009 307 HIV vaccine trial stopped infection; researchers find. Brief article Sep 24, 2009 159 FAB Pharma, a Biopharma Company Developing Drugs to Treat Severe Bacterial Infections, Raises [euro]2.3 Million in Series A Funding and Begins Recruitment for a Phase I Trial of Its Lead Compound. Sep 12, 2009 431 Acorda Therapeutics Announces Interim Analysis of Two-Year Efficacy and Safety Data from Phase 3 Fampridine-SR Extension Study. Clinical report Sep 10, 2009 1382 StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder. Sep 10, 2009 1948 Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma. Sep 8, 2009 700 Array BioPharma Announces Top-Line Results from Rheumatoid Arthritis Phase 2 Trial. Clinical report Sep 3, 2009 1620 United States: FDA approves ATS heart-valve trial. Aug 28, 2009 191 Geron Comments on FDA Hold on Spinal Cord Injury Trial. Aug 27, 2009 498 Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug. Aug 25, 2009 334 United States : Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin. Aug 25, 2009 476 Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin Lymphoma. Aug 24, 2009 1249 United States : Sinovac Biotech announces positive results from clinical trial of H1N1 vaccine. Aug 19, 2009 432 Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune. Aug 10, 2009 654 Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial. Jul 24, 2009 763 Can-Fite BioPharma to Initiate Phase I/II Clinical Trial with CF102 for the Treatment of Hepatitis C Virus. Jul 14, 2009 547 Mid-Day Minute - July 14. Financial report Jul 14, 2009 519 Midday minute - July 14 - Energy. Jul 14, 2009 129 Daily News Wrap Up - July 14. Financial report Jul 14, 2009 583 Medarex to Receive Milestone Payment from FibroGen for the Initiation of a Phase 2 Study of FG-3019 in Patients with Diabetic Kidney Disease. Jul 13, 2009 505 Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial in Mixed Dyslipidemia. Jul 9, 2009 1317 Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis. Jul 8, 2009 504 Array BioPharma Announces Top-Line Results in Two Phase 1 Clinical Trials. Financial report Jul 8, 2009 1656 Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S. Jul 1, 2009 1324 Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis. Jun 22, 2009 795 Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma. Jun 18, 2009 862 WHO urges drug makers to meet pandemic demand. Brief article Jun 11, 2009 280 Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis. Clinical report Jun 10, 2009 1101 Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data. Jun 8, 2009 924 Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma. Jun 8, 2009 937 StemCells, Inc. Announces Positive Phase I Batten Trial Results. Jun 8, 2009 2470 StemCells, Inc. to Present Phase I Clinical Trial Results at the 12th International Congress on NCL. Jun 1, 2009 916 Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma. Jun 1, 2009 1265 Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg). Clinical report May 31, 2009 1905 Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer. May 30, 2009 1676 Aphios Announces Presentation of Phase II/III Clinical Trial Data on Zindol[R] for Cancer Chemotherapy Induced Nausea. May 26, 2009 487 Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress. May 21, 2009 753 Independent Data Monitoring Board Recommends Continuation to Completion of Genta's Phase 3 Trial of Genasense[R] in Advanced Melanoma. May 19, 2009 900 Northfield Laboratories Announces Decision to Wind Down Business. May 16, 2009 430 Seattle Genetics Announces SGN-35 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting. May 14, 2009 648 Inhibitex Initiates Phase II Clinical Trial of FV-100 for the Treatment of Shingles. May 8, 2009 841 Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients. May 8, 2009 1614 Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Cardiovascular Trial. May 6, 2009 1019 CAN-FITE BIOPHARMA TO INITIATE CF102 TRIAL FOR LIVER CANCER. May 1, 2009 528 Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense[R] in Advanced Melanoma. Apr 29, 2009 1084 Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR. Apr 22, 2009 828 Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV. Apr 17, 2009 2652 Can-Fite BioPharma to Initiate Phase I/II Clinical Trial With CF102 for the Treatment of Liver Cancer. Apr 16, 2009 574 Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009. Apr 13, 2009 438 Array BioPharma Initiates Clinical Trial in Type 2 Diabetic Patients. Apr 8, 2009 896 Genta Announces Completion of Patient Enrollment into Global Phase 3 Trial of Genasense[R] in Advanced Melanoma. Apr 7, 2009 882 Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints. Apr 2, 2009 1296 tensVida wins NutrAward. Brief article Apr 1, 2009 55 VGX Pharmaceuticals' Oral Anti-Inflammatory Drug Safe in Phase I Study. Mar 26, 2009 367 Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension. Mar 24, 2009 921 Approval sought: MannKind Corp. said it filed for U.S. Food and Drug Administration approval to market Afresa, its inhaled insulin product for diabetics. Brief article Mar 23, 2009 91 FDA Appeal Decision Indicates that Genasense[R] Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial. Mar 6, 2009 738 ImmunoGen, Inc. Earns Milestone Payment with Genentech's Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported. Mar 2, 2009 498 Cell Genesys Announces Final Results from Phase 3 Program of GVAX Immunotherapy for Prostate Cancer. Financial report Feb 27, 2009 1220 Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia. Feb 25, 2009 696 GTC Biotherapeutics Licenses JCOM To Develop Recombinant Human Insulin Products for Asia. Feb 23, 2009 576 Curis Announces Genentech's Initiation of Pivotal Phase II Trial of GDC-0449 in Advanced Basal Cell Carcinoma. Feb 12, 2009 509 Inhibitex Completes Phase I Clinical Trials for FV-100 and Selects Lead HCV Compounds for Advanced Preclinical Studies. Feb 9, 2009 1388 FDA Allows Trial of Human Stem Cells. Feb 1, 2009 199 Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin Lymphoma. Jan 21, 2009 1131 Curis Announces Genentech's Expected Initiation of Pivotal Phase II Trial in Advanced Basal Cell Carcinoma with Hedgehog Pathway Inhibitor. Jan 15, 2009 938 Genta Initiates New Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development. Jan 14, 2009 1018 Genta Updates Late-Stage Progress of Its Phase 3 Trial of Genasense[R] in Advanced Melanoma. Clinical report Jan 12, 2009 1138 Array BioPharma Initiates Phase 1 Clinical Trial for MEK Inhibitor ARRY-300. Jan 9, 2009 659 Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine. Jan 8, 2009 730 StemCells, Inc. Receives FDA Approval to Initiate Clinical Trial of HuCNS-SC[R] Cells in a Myelin Disease. Dec 18, 2008 1074 Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial. Dec 10, 2008 748 Curis Announces Genentech's Initiation of Phase II Clinical Trial in Advanced Ovarian Cancer with Hedgehog Pathway Inhibitor. Dec 8, 2008 845 Dynavax Presents Preclinical Data Supporting Its Novel Universal Flu Vaccine Candidate. Dec 8, 2008 732 Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial. Dec 6, 2008 995 Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage[R] Cancer Vaccine in Glioma Presented at the Society for Neuro-Oncology's Annual Meeting. Nov 24, 2008 904 Cerus Initiates Phase I Clinical Trial for INTERCEPT Red Blood Cell System. Nov 24, 2008 583 Working with U.S. Department of Defense, Canopus BioPharma Announces Phase II Human Clinical Trial for Innovative Hepatitis C Drug, CB5300. Nov 4, 2008 542 Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B. Nov 1, 2008 2877 Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs. Oct 24, 2008 804 Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis. Oct 23, 2008 1181 Cyclacel to Present Preclinical Data Showing Synergy of Combination of Sapacitabine with Histone Deacetylating Agents. Oct 21, 2008 788 Bacteria-based immune therapy targets liver metastases. Brief article Jan 1, 2007 255 IND for MDX-1401. Brief article Jan 1, 2007 170